NO20076456L - Sammensetninger som omfatter et cefalosporin i nanopartikkelform og med kontrollert frigjoring - Google Patents

Sammensetninger som omfatter et cefalosporin i nanopartikkelform og med kontrollert frigjoring

Info

Publication number
NO20076456L
NO20076456L NO20076456A NO20076456A NO20076456L NO 20076456 L NO20076456 L NO 20076456L NO 20076456 A NO20076456 A NO 20076456A NO 20076456 A NO20076456 A NO 20076456A NO 20076456 L NO20076456 L NO 20076456L
Authority
NO
Norway
Prior art keywords
cephalosporin
nanoparticle
shaped
controlled release
particles
Prior art date
Application number
NO20076456A
Other languages
English (en)
Norwegian (no)
Inventor
Paul Stark
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076456L publication Critical patent/NO20076456L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20076456A 2005-05-16 2007-12-14 Sammensetninger som omfatter et cefalosporin i nanopartikkelform og med kontrollert frigjoring NO20076456L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68126505P 2005-05-16 2005-05-16
PCT/US2006/018835 WO2008010784A1 (en) 2005-05-16 2006-05-16 Nanoparticulate and controlled release compositions comprising a cephalosporin

Publications (1)

Publication Number Publication Date
NO20076456L true NO20076456L (no) 2008-02-13

Family

ID=38957038

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076456A NO20076456L (no) 2005-05-16 2007-12-14 Sammensetninger som omfatter et cefalosporin i nanopartikkelform og med kontrollert frigjoring

Country Status (14)

Country Link
US (1) US20090269400A1 (pt)
EP (1) EP1915139A1 (pt)
JP (1) JP2008540691A (pt)
KR (1) KR20080026109A (pt)
CN (1) CN101287453A (pt)
AU (1) AU2006344711A1 (pt)
BR (1) BRPI0614080A2 (pt)
CA (1) CA2609296A1 (pt)
EA (1) EA200702518A1 (pt)
IL (1) IL187431A0 (pt)
MX (1) MX2007014363A (pt)
NO (1) NO20076456L (pt)
WO (1) WO2008010784A1 (pt)
ZA (1) ZA200709761B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057266A2 (en) * 2009-11-09 2011-05-12 Board Of Regents, The University Of Texas System Emulsion template method to form small particles of hydrophobic agents with surface enriched hydrophilicity by ultra rapid freezing
CN101874784B (zh) * 2010-03-18 2011-12-14 贝沃特医药技术(上海)有限公司 析出结晶药物缓控释微球粒及其制备方法
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
US20150238425A1 (en) 2012-08-28 2015-08-27 Dsm Sinochem Pharmaceuticals Netherlands B.V. Mini-tablets
CN103980480B (zh) * 2013-02-07 2018-08-17 杨子剑 一种接枝药物的聚合物的制备和用途
KR101509168B1 (ko) * 2013-06-10 2015-04-06 한국화학연구원 세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물
CN103330697B (zh) * 2013-06-27 2015-03-11 深圳致君制药有限公司 一种头孢丙烯胶囊及其制备方法
RO132297A2 (ro) * 2014-12-01 2017-12-29 Sun Pharmaceutical Industries Limited Compoziţie cu cefpodoxim proxetil cu eliberare extinsă
CN112675152A (zh) * 2020-12-25 2021-04-20 厦门金达威生物科技有限公司 一种nmn缓释肠溶性微胶囊及其制备方法
CN115487154B (zh) * 2022-11-17 2023-02-21 山东国邦药业有限公司 一种盐酸多西环素颗粒剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5935496A (en) * 1993-04-29 1999-08-10 Morton International, Inc. Salt pelletizing method
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
IN191496B (pt) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR100342944B1 (ko) * 1999-11-08 2002-07-02 민경윤 고순도 세프포독심 프록세틸의 제조방법
EP1320362B1 (en) * 2000-09-20 2011-08-31 Jagotec AG Stabilised fibrate microparticles
ATE303149T1 (de) * 2001-02-27 2005-09-15 Ranbaxy Lab Ltd Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs

Also Published As

Publication number Publication date
US20090269400A1 (en) 2009-10-29
CN101287453A (zh) 2008-10-15
KR20080026109A (ko) 2008-03-24
MX2007014363A (es) 2009-04-15
EP1915139A1 (en) 2008-04-30
WO2008010784A1 (en) 2008-01-24
IL187431A0 (en) 2011-08-01
BRPI0614080A2 (pt) 2017-07-25
AU2006344711A1 (en) 2008-01-24
CA2609296A1 (en) 2006-11-16
JP2008540691A (ja) 2008-11-20
EA200702518A1 (ru) 2008-04-28
ZA200709761B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
NO20076456L (no) Sammensetninger som omfatter et cefalosporin i nanopartikkelform og med kontrollert frigjoring
Sivakumar et al. Incorporation of antimicrobial macromolecules in acrylic denture base resins: a research composition and update
Prasanna et al. Sustained release of amoxicillin from hydroxyapatite nanocomposite for bone infections
Ernst et al. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions
Hayat et al. In vitro antibiofilm and anti‐adhesion effects of magnesium oxide nanoparticles against antibiotic resistant bacteria
Liao et al. Mesoporous hydroxyapatite/chitosan loaded with recombinant-human amelogenin could enhance antibacterial effect and promote periodontal regeneration
Tan et al. The use of quaternised chitosan-loaded PMMA to inhibit biofilm formation and downregulate the virulence-associated gene expression of antibiotic-resistant staphylococcus
Neethirajan et al. Medical biofilms—nanotechnology approaches
Zhao et al. Influence of silver-hydroxyapatite nanocomposite coating on biofilm formation of joint prosthesis and its mechanism
Tambone et al. Rhamnolipid coating reduces microbial biofilm formation on titanium implants: an in vitro study
Habimana et al. One particle, two targets: A combined action of functionalised gold nanoparticles, against Pseudomonas fluorescens biofilms
Sehgal et al. Mechanically stiff, zinc cross-linked nanocomposite scaffolds with improved osteostimulation and antibacterial properties
Izbudak et al. Layered double hydroxide-based nanocomposite scaffolds in tissue engineering applications
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
Tan et al. Carboxymethyl chitosan prevents formation of broad-spectrum biofilm
Zarghami et al. Prolongation of bactericidal efficiency of chitosan—Bioactive glass coating by drug controlled release
Larissa et al. Development, characterization and antimicrobial activity of multilayer silica nanoparticles with chlorhexidine incorporated into dental composites
Yahya et al. Biosynthesized silver nanoparticles-capped chondroitin sulfate nanogel targeting microbial infections and biofilms for biomedical applications
Teng et al. Novel probiotics adsorbing and excreting microplastics in vivo show potential gut health benefits
Cheng et al. Selenium-modified TiO2 nanoarrays with antibacterial and anticancer properties for postoperation therapy applications
Nganga et al. In vitro antimicrobial properties of silver–polysaccharide coatings on porous fiber-reinforced composites for bone implants
Aguzzi et al. Health and medical applications of tubular clay minerals
Temsaah et al. Chitosan nano-formulation enhances stability and bactericidal activity of the lytic phage HK6
Asokan et al. Biogenic ZnO nanoparticle-coated endotracheal tubes: A study on their biocompatibility and antibacterial activity
Tan et al. A multifunctional dexamethasone-delivery implant fabricated using atmospheric plasma and its effects on apoptosis, osteogenesis and inflammation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application